Abstract
Peroxisome Proliferator-Activated Receptor-γ (PPARγ) is an extensively studied ligand-activated nuclear hormone receptor that functions as transcription factor and plays an important role in diverse biological processes, such as lipid metabolism and insulin sensitization. Recent studies have demonstrated that PPARγ is over-expressed in many tumor types, including breast cancer, suggesting a possible role in tumor development and/or progression and a putative prognostic value. Moreover, naturally-occurring and synthetic PPARγ agonists promote growth inhibition, apoptosis and differentiation of tumor cells. The present review summarizes the available information on PPARγ expression in breast tumors and the use of PPARγ ligands as anti-cancer agents for breast cancer treatment, both in vitro and in vivo. Considering the data so far, specific PPARγ agonists seem to exert beneficial effects against breast cancer and may therefore represent potential therapeutic agents.
Keywords: 15-deoxy-Δ12, 14-prostaglandin J2 (15d-PGJ2), Anti-cancer agents, Apoptosis, Breast cancer, Cell cycle arrest, Differentiation, Estrogen Receptors (ERs), Fatty acids, Growth inhibition, Ligands, Methylene-substituted diindolylmetyhanes (CDIMs), Oncogenesis, Peroxisome Proliferator-Activated Receptor-γ (PPARγ), Prognostic value, Retinoid-X-Receptor (RXR), Statins, Thiazolidinediones (TZDs)
Anti-Cancer Agents in Medicinal Chemistry
Title:The Role of Peroxisome Proliferator-Activated Receptor-γ in Breast Cancer
Volume: 12 Issue: 9
Author(s): Ioly Kotta-Loizou, Constantinos Giaginis and Stamatios Theocharis
Affiliation:
Keywords: 15-deoxy-Δ12, 14-prostaglandin J2 (15d-PGJ2), Anti-cancer agents, Apoptosis, Breast cancer, Cell cycle arrest, Differentiation, Estrogen Receptors (ERs), Fatty acids, Growth inhibition, Ligands, Methylene-substituted diindolylmetyhanes (CDIMs), Oncogenesis, Peroxisome Proliferator-Activated Receptor-γ (PPARγ), Prognostic value, Retinoid-X-Receptor (RXR), Statins, Thiazolidinediones (TZDs)
Abstract: Peroxisome Proliferator-Activated Receptor-γ (PPARγ) is an extensively studied ligand-activated nuclear hormone receptor that functions as transcription factor and plays an important role in diverse biological processes, such as lipid metabolism and insulin sensitization. Recent studies have demonstrated that PPARγ is over-expressed in many tumor types, including breast cancer, suggesting a possible role in tumor development and/or progression and a putative prognostic value. Moreover, naturally-occurring and synthetic PPARγ agonists promote growth inhibition, apoptosis and differentiation of tumor cells. The present review summarizes the available information on PPARγ expression in breast tumors and the use of PPARγ ligands as anti-cancer agents for breast cancer treatment, both in vitro and in vivo. Considering the data so far, specific PPARγ agonists seem to exert beneficial effects against breast cancer and may therefore represent potential therapeutic agents.
Export Options
About this article
Cite this article as:
Kotta-Loizou Ioly, Giaginis Constantinos and Theocharis Stamatios, The Role of Peroxisome Proliferator-Activated Receptor-γ in Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (9) . https://dx.doi.org/10.2174/187152012803529664
DOI https://dx.doi.org/10.2174/187152012803529664 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
RNA Interference and Potential Applications
Current Topics in Medicinal Chemistry Cathelicidins: Peptides with Antimicrobial, Immunomodulatory, Anti- Inflammatory, Angiogenic, Anticancer and Procancer Activities
Current Protein & Peptide Science New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems Editorial [Hybrid Imaging (Guest Editors: Birger Hesse and Abass Alavi)]
Current Medical Imaging Editorial (Thematic Issue: Antitumor Alkylphospholipid Analogs: A Promising and Growing Family of Synthetic Cell Membrane-Targeting Molecules for Cancer Treatment)
Anti-Cancer Agents in Medicinal Chemistry Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry MicroRNA Gene Networks in Oncogenesis
Current Genomics Design, Synthesis, and Evaluation of (2-(Pyridinyl)methylene)-1-tetralone Chalcones for Anticancer and Antimicrobial Activity
Medicinal Chemistry Thiopurine Immunomodulators in Ulcerative Colitis: Moving Forward with Current Evidence
Current Drug Targets Novel Monocyte Biomarkers of Atherogenic Conditions
Current Pharmaceutical Design Illuminating microRNA Transcription from the Epigenome
Current Genomics Actionable Nutrigenetics for Genetically Based Diseases? A New Critical Path to P4 Medicine
Current Pharmacogenomics and Personalized Medicine Synthesis and Biological Activity of 3-(substitutedphenyl)- 6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Is there a Potential Immune Dysfunction with Anabolic Androgenic Steroid Use?: A Review
Mini-Reviews in Medicinal Chemistry Current Status of CT Colonography
Current Medical Imaging Monitoring Molecular, Functional and Morphologic Aspects of Bone Metastases Using Non-Invasive Imaging
Current Pharmaceutical Biotechnology Pegylated Naloxone in the Treatment of Persistent Opioid-Induced Constipation in Patients with Hematological Malignancies
Cardiovascular & Hematological Agents in Medicinal Chemistry Technetium Labeled Small Peptide Radiopharmaceuticals in the Identification of Lung Cancer
Current Pharmaceutical Design The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism